  0 Table of Contents |
  1 Introduction |
| 2 Evidence Profiles |
| 3 EvidenceVariable Profiles |
| 4 Group Profiles |
| 5 PublicationRecord Profiles |
| 6 ArtifactAssessment Profiles |
| 7 Composition Profiles |
| 8 Other Profiles |
| 9 Profiles |
| 10 Extensions |
| 11 Terminologies |
| 12 Examples |
| 13 Downloads |
| 14 Changes |
 15 Artifacts Summary |
 15.1 AbsenceOfExposureDefinition |
| 15.2 Adaptation |
| 15.3 AdverseEventsReport |
| 15.4 BaselineMeasureEvidence |
| 15.5 BaselineMeasureReport |
| 15.6 BaselineVariablesList |
| 15.7 BookCitation |
| 15.8 BookPartCitation |
| 15.9 CertaintyOfEvidence |
| 15.10 Classification |
| 15.11 CohortDefinition |
| 15.12 Comment |
| 15.13 ComparativeBaselineMeasureEvidence |
| 15.14 ComparativeEvidence |
| 15.15 ComparativeEvidenceReport |
| 15.16 ComparativeEvidenceReportExpanded |
| 15.17 ComparativeEvidenceReportSubject |
| 15.18 ComparativeEvidenceSynthesisReport |
| 15.19 ComparativeParticipantFlowEvidence |
| 15.20 ComparatorGroup |
| 15.21 ComparatorOnlyEvidence |
| 15.22 Comparison |
| 15.23 CompositeRating |
| 15.24 ConceptualCohortDefinition |
| 15.25 ConceptualComparatorDefinition |
| 15.26 ConceptualExposureDefinition |
| 15.27 DatabaseCitation |
| 15.28 DatabaseEntryCitation |
| 15.29 DatasetCitation |
| 15.30 DateAsRating |
| 15.31 DichotomousIntendedOutcome |
| 15.32 EndpointAnalysisPlan |
| 15.33 EvidenceAssessment |
| 15.34 EvidenceList |
| 15.35 EvidenceReport |
| 15.36 EvidenceReportPackage |
| 15.37 EvidenceReportSubject |
| 15.38 EvidenceSynthesisEvidence |
| 15.39 ExposureGroup |
| 15.40 GroupAssignment |
| 15.41 GroupR6 |
| 15.42 Guideline |
| 15.43 InterventionOnlyEvidence |
| 15.44 JournalArticleCitation |
| 15.45 M11ReportContainer |
| 15.46 M11ReportSection01 |
| 15.47 M11ReportSection02 |
| 15.48 M11ReportSection03 |
| 15.49 M11ReportSection04 |
| 15.50 M11ReportSection05 |
| 15.51 M11ReportSection06 |
| 15.52 M11ReportSection07 |
| 15.53 M11ReportSection08 |
| 15.54 M11ReportSection09 |
| 15.55 M11ReportSection10 |
| 15.56 M11ReportSection11 |
| 15.57 M11ReportSection12 |
| 15.58 M11ReportSection13 |
| 15.59 M11ReportSection14 |
| 15.60 M11ResearchStudy |
| 15.61 MetaanalysisEligibilityCriteria |
| 15.62 MetaanalysisOutcomeDefinition |
| 15.63 MetaanalysisStudyGroup |
| 15.64 NetEffectContribution |
| 15.65 NetEffectContributionList |
| 15.66 NetEffectContributions |
| 15.67 NetEffectEstimate |
| 15.68 NonComparativeEvidence |
| 15.69 OutcomeDefinition |
| 15.70 OutcomeImportance |
| 15.71 OutcomeList |
| 15.72 OutcomeMeasureReport |
| 15.73 OutcomeVariablesList |
| 15.74 ParticipantFlowEvidence |
| 15.75 ParticipantFlowEvidenceVariable |
| 15.76 ParticipantFlowReasonEvidenceVariable |
| 15.77 ParticipantFlowReport |
| 15.78 ParticipantFlowVariablesList |
| 15.79 PICOSpecification |
| 15.80 PICOTaggedComposition |
| 15.81 PICOTaggedEvidence |
| 15.82 PreprintCitation |
| 15.83 Rating |
| 15.84 Recommendation |
| 15.85 RecommendationAction |
| 15.86 RecommendationEligibilityCriteria |
| 15.87 RecommendationJustification |
| 15.88 RecommendationPlan |
| 15.89 RecommendationRating |
| 15.90 ResearchStudyDataDictionary |
| 15.91 ResearchStudySite |
| 15.92 ResearchStudySupport |
| 15.93 RiskOfBias |
| 15.94 SearchResults |
| 15.95 SearchStrategy |
| 15.96 SingleStudyEvidence |
| 15.97 SoaPlanDefinition |
| 15.98 SoftwareCitation |
| 15.99 StatisticModel |
| 15.100 StudyComponent |
| 15.101 StudyDesign |
| 15.102 StudyEligibilityCriteria |
| 15.103 StudyGroup |
| 15.104 StudyRegistryRecord |
| 15.105 SummaryOfFindings |
| 15.106 SummaryOfNetEffect |
| 15.107 SystematicReview |
| 15.108 SystematicReviewEligibilityCriteria |
| 15.109 SystematicReviewExcludedStudies |
| 15.110 SystematicReviewIncludedStudies |
| 15.111 VariableDefinition |
| 15.112 WebPageCitation |
| 15.113 ArtifactAssessmentCompared |
| 15.114 ArtifactAssessmentDateAsRating |
| 15.115 ArtifactPublicationStatus |
| 15.116 ArtifactRecorder |
| 15.117 CharacteristicTiming |
| 15.118 CiteAs |
| 15.119 GuidelineRegistration |
| 15.120 M11AmendmentDetail |
| 15.121 M11AmendmentScopeImpact |
| 15.122 NumberAnalyzed |
| 15.123 RelatesToClassifier |
| 15.124 RelatesToWithQuotation |
| 15.125 RelativeOutcomeImportance |
| 15.126 RelevantForAutomatedMatching |
| 15.127 ResearchStudyExcludedStudy |
| 15.128 ResearchStudyIncludedStudy |
| 15.129 ResearchStudyIsLowInterventionTrial |
| 15.130 ResearchStudyIsRareDisease |
| 15.131 ResearchStudyM11Approval |
| 15.132 ResearchStudyM11ProtocolAmendment |
| 15.133 ResearchStudyNumberOfStudiesIdentified |
| 15.134 ResearchStudyNumberOfStudiesIncluded |
| 15.135 ResearchStudySaeReportingMethod |
| 15.136 ResearchStudySearchStrategy |
| 15.137 ResearchStudySponsorConfidentialityStatement |
| 15.138 ResearchStudyStudyAmendment |
| 15.139 ResearchStudySystematicReviewEligibilityCriteria |
| 15.140 ResearchStudyVersionDate |
| 15.141 StatisticModelExpression |
| 15.142 StatisticModelIncludeIf |
| 15.143 Desirability Codes Value Set |
| 15.144 EBMonFHIR Profile Name Value Set |
| 15.145 Evidence Rating System Classifier Codes Value Set |
| 15.146 ICH M11 Amendment Details Statement Value Set |
| 15.147 ICH M11 Amendment Scope Enrollment Value Set |
| 15.148 ICH M11 Amendment Scope Value Set |
| 15.149 ICH M11 Reason for Amendment Value Set |
| 15.150 ICH M11 Trial Phase Value Set |
| 15.151 ICH M11 Yes No Value Set |
| 15.152 Limited M11 Section Codes Value Set |
| 15.153 PICO Classification Value Set |
| 15.154 Recommendation Justification Classifier Codes Value Set |
| 15.155 Research Study Document Types Value Set |
| 15.156 ResearchStudy Classifier Value Set |
| 15.157 Search Strategy Characteristic Value Set |
| 15.158 UDP Identifier Type Value Set |
| 15.159 UDP Party Role Type Value Set |
| 15.160 Desirability Code System |
| 15.161 EBMonFHIR Profile Name Code System |
| 15.162 Evidence Rating System Classifier Code System |
| 15.163 Research Study Document Types Code System |
| 15.164 Search Strategy Characteristic Code System |
| 15.165 11232013 Rosiglitazone monotherapy is effective in patients with type 2 diabetes. |
| 15.166 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
| 15.167 14706014 Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. |
| 15.168 15832493 Spotlight on rosiglitazone in the management of type 2 diabetes mellitus. |
| 15.169 15855602 Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. |
| 15.170 179899 |
| 15.171 18160893 Wonder woman. Like my childhood heroine, Mrs. Betty also had amazing powers. |
| 15.172 18508207 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. |
| 15.173 19029421 Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. |
| 15.174 19091394 Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. |
| 15.175 19967827 Wonder woman was Argentine and her real name was Evita. |
| 15.176 22056152 Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. |
| 15.177 22502942 Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. |
| 15.178 23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. |
| 15.179 23452809 Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer. |
| 15.180 23589542 Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. |
| 15.181 23604530 A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. |
| 15.182 24598155 Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. |
| 15.183 25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). |
| 15.184 26002607 Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. |
| 15.185 26028518 Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. |
| 15.186 26092557 Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer. |
| 15.187 26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. |
| 15.188 26502880 A novel nasal powder formulation of glucagon: toxicology studies in animal models. |
| 15.189 26681725 Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study. |
| 15.190 26859072 Emotional Distress in the Partners of Type 1 Diabetes Adults: Worries About Hypoglycemia and Other Key Concerns. |
| 15.191 27222544 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. |
| 15.192 27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis. |
| 15.193 27979893 6. Glycemic Targets. |
| 15.194 29114761 Web Exclusives. Annals Story Slam - How Wonder Woman Became My Alter Ego. |
| 15.195 29114762 Web Exclusives. Annals Story Slam - Wonder Woman Is a Cartoon Character. |
| 15.196 29202628 "I Kinda Feel Like Wonder Woman": An Interpretative Phenomenological Analysis of Pole Fitness and Positive Body Image. |
| 15.197 29357271 Using Hawkeye from the Avengers to communicate on the eye. |
| 15.198 29694275 A regressive formula of perversity: Wertham and the women of comics. |
| 15.199 29694302 Introduction: "Suffering Sappho!": Lesbian content and queer female characters in comics. |
| 15.200 30467172 Finding my inner Wonder Woman. |
| 15.201 30545967 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. |
| 15.202 33008778 Association of corticosteroids use and outcomes in COVID-19 patients: A systematic review and meta-analysis. |
| 15.203 34871555 What Can Wonder Woman Teach Radiologists? |
| 15.204 35243488 Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis. |
| 15.205 36491989 Another Georgia Wonder Woman: She Does More Astounding Tricks Than Did Lula Hurst. |
| 15.206 367832 |
| 15.207 367833 |
| 15.208 37024129 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. |
| 15.209 38584159 Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial. |
| 15.210 6907780 Career guide: to change what needs changing...doesn't take Wonder Woman. |
| 15.211 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus |
| 15.212 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.213 ADAS-Cog(11) EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
| 15.214 Add-on Amlodipine at 6 weeks |
| 15.215 Adults hospitalized with COVID-19 pneumonia |
| 15.216 Adults with diabetes mellitus type 2 |
| 15.217 Adults with type 2 diabetes and CVD and CKD |
| 15.218 Adults with type 2 diabetes and established CVD (but no CKD) |
| 15.219 Adverse event free and hypertension control |
| 15.220 Adverse event free and hypertension control at 12 weeks |
| 15.221 Adverse Events Report for NCT03421379 |
| 15.222 Adverse Events Report for NCT03640312 |
| 15.223 Age |
| 15.224 Age with comparator |
| 15.225 Age with intervention |
| 15.226 Aircraft Type |
| 15.227 Aircraft Type with comparator |
| 15.228 Aircraft Type with intervention |
| 15.229 Altitude |
| 15.230 Altitude comparing intervention vs. comparator |
| 15.231 Altitude for enrolled group |
| 15.232 Altitude for screened group |
| 15.233 Altitude with comparator |
| 15.234 Altitude with intervention |
| 15.235 Analysis of formalin-fixed paraffin-embedded and blood and blood samples (NCT05327010) |
| 15.236 Analyzed Group in PARACHUTE Trial |
| 15.237 Anticoagulation for COVID-19 Combined RCTs in NEJM |
| 15.238 Anticoagulation for COVID-19 Combined RCTs PrePrint |
| 15.239 Assess emergent resistant mutations (NCT05327010) |
| 15.240 Baseline Characteristics Report for NCT03421379 |
| 15.241 Baseline Characteristics Report for NCT03640312 |
| 15.242 Baseline Characteristics Report for QUARTET Trial |
| 15.243 Baseline Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
| 15.244 Baseline Measures List for PARACHUTE Trial |
| 15.245 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Medical Group |
| 15.246 BaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group |
| 15.247 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Medical Group |
| 15.248 BaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group |
| 15.249 BaselineVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
| 15.250 Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials |
| 15.251 BookCitation: Crossing the Quality Chasm: A New Health System for the 21st Century |
| 15.252 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century |
| 15.253 BookPartCitation: Chapter 3 of Crossing the Quality Chasm: A New Health System for the 21st Century - without baseCitation |
| 15.254 BP-CONTROL Cardiovascular Outcomes Component: intensive versus standard blood-pressure control in adults at increased cardiovascular risk |
| 15.255 BP-CONTROL Master Protocol: blood-pressure targets in adults at increased cardiovascular risk |
| 15.256 Candesartan 8 mg once daily |
| 15.257 Certainty of Evidence Rating of 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
| 15.258 Change in Mean Diastolic Blood Pressure (NCT03640312) |
| 15.259 Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 |
| 15.260 Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 |
| 15.261 Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.262 Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312) |
| 15.263 Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312 |
| 15.264 Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.265 Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.266 Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312) |
| 15.267 Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 |
| 15.268 Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 |
| 15.269 Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.270 CIBIC+ EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
| 15.271 Citation for Composition: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
| 15.272 Citation for EBMonFHIR Implementation Guide |
| 15.273 Citation for FEvIR Evidence 55: 14-day mortality remdesivir vs placebo meta-analysis (ACTT-1, Wang et al, WHO SOLIDARITY) |
| 15.274 Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19 |
| 15.275 Classification: Study Design for Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort |
| 15.276 Clinical benefit rate (CBR) (NCT05327010) |
| 15.277 Comment on Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes by Joanne Dehnbostel 2023-11-28T15:19:01.266Z |
| 15.278 Comparative Evidence Report Expanded for QUARTET USA Trial |
| 15.279 Comparative Evidence Report for QUARTET USA Trial |
| 15.280 ComparativeBaselineMeasureEvidence: Age in 2018 Norwegian Cohort Surgical Group vs. Medical Group |
| 15.281 ComparativeBaselineMeasureEvidence: BMI in 2018 Norwegian Cohort Surgical Group vs. Medical Group |
| 15.282 ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis |
| 15.283 ComparativeEvidence: Bariatric Surgery effect for ADA triple outcome at 5 years (Diabetes Surgery Study) |
| 15.284 ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study |
| 15.285 ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study |
| 15.286 ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study |
| 15.287 ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study |
| 15.288 ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study |
| 15.289 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2014 |
| 15.290 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Courcoulas 2015 |
| 15.291 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Cummings 2016 |
| 15.292 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ding 2015 |
| 15.293 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Dixon 2008 |
| 15.294 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Halperin 2014 |
| 15.295 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2013 |
| 15.296 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Ikramuddin 2015 |
| 15.297 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Liang 2013 |
| 15.298 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2012 (DIBASY) trial |
| 15.299 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Mingrone 2015 (DIBASY) trial |
| 15.300 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Parikh 2014 |
| 15.301 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2012 (STAMPEDE) trial |
| 15.302 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Schauer 2014 (STAMPEDE) trial |
| 15.303 ComparativeEvidence: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups in Wentworth 2014 |
| 15.304 ComparativeEvidence: Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis |
| 15.305 ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
| 15.306 ComparativeEvidenceReportSubject: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
| 15.307 ComparativeEvidenceSynthesisReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.308 ComparativeParticipantFlowEvidence: Dropout due to stopping intervention Lofexidine vs. Placebo in opioid detoxification trial |
| 15.309 ComparatorDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists |
| 15.310 ComparatorDefinition: Obese patients ≥ 18 years old without bariatric surgery |
| 15.311 ComparatorDefinition: Standard care |
| 15.312 ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort |
| 15.313 ComparatorOnlyEvidence: Additional GI surgical procedure without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
| 15.314 ComparatorOnlyEvidence: All-cause mortality without bariatric surgery in 2022 meta-analysis |
| 15.315 ComparatorOnlyEvidence: Myocardial infarction or stroke without bariatric surgery (Control Group) in Swedish Obese Subjects (SOS) study |
| 15.316 ComparatorOnlyEvidence: New onset depression without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
| 15.317 ComparatorOnlyEvidence: Remission of diabetes without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
| 15.318 ComparatorOnlyEvidence: Treatment with opioids without bariatric surgery (Control Group) in JAMA 2018 Norwegian cohort study |
| 15.319 Comparison: Original and Adapted Recommendation: ADA Obesity Management Recommendation 8.16 |
| 15.320 Composite Rating of FOI 153881 for Project FOI 112280 |
| 15.321 Computable_Publishing_LLC |
| 15.322 ConceptualCohortDefinition: At least 2 risk factors for stroke |
| 15.323 ConceptualCohortDefinition: BMI 27.5-32.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery |
| 15.324 ConceptualCohortDefinition: BMI 30-34.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery |
| 15.325 ConceptualCohortDefinition: BMI 32.5-37.4 in Asian Americans who do not achieve durable weight loss and improvement in comorbidities without surgery |
| 15.326 ConceptualCohortDefinition: BMI 35-39.9 in persons who do not achieve durable weight loss and improvement in comorbidities without surgery |
| 15.327 ConceptualCohortDefinition: BMI criteria for ADA surgery recommendation |
| 15.328 ConceptualCohortDefinition: BMI ≥ 35 and at least 1 obesity-related comorbidity |
| 15.329 ConceptualCohortDefinition: BMI ≥ 37.5 kg/m2 in Asian Americans |
| 15.330 ConceptualCohortDefinition: Estimated glomerular filtration rate 45-59 |
| 15.331 ConceptualCohortDefinition: Heart failure based on Phenotypes |
| 15.332 ConceptualCohortDefinition: Lower BMI criteria for ADA surgery consideration |
| 15.333 ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria |
| 15.334 ConceptualCohortDefinition: Nonfatal myocardial infarction |
| 15.335 ConceptualCohortDefinition: Nonfatal stroke |
| 15.336 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter |
| 15.337 ConceptualCohortDefinition: Oxygen saturation below 96% on Boots Finger Pulse Oximeter with Ranges |
| 15.338 ConceptualCohortDefinition: Proxy criteria for surgical candidates |
| 15.339 ConceptualCohortDefinition: Severe obesity |
| 15.340 ConceptualCohortDefinition: T1DM or T2DM |
| 15.341 ConceptualCohortDefinition: T1DM-specific criteria |
| 15.342 ConceptualCohortDefinition: T2DM-specific criteria |
| 15.343 ConceptualCohortDefinition_Cancer_of_any_kind_except_basal_cell_skin_cancer_or_cancer_in_situ_unless_documented_to_be_disease_free_for_five_years |
| 15.344 ConceptualCohortDefinition_Cardiovascular_event |
| 15.345 ConceptualComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD) |
| 15.346 ConceptualComparatorDefinition: Usual-care pharmacologic thromboprophylaxis |
| 15.347 ConceptualExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) |
| 15.348 ConceptualExposureDefinition: Therapeutic-dose anticoagulation with heparin |
| 15.349 Correlate baseline mutations with treatment response (NCT05327010) |
| 15.350 Correlate changes in ctDNA variant allele frequencies with response (NCT05327010) |
| 15.351 Correlate mutation profiles with tumor sequencing (NCT05327010) |
| 15.352 Correlation of single nucleotide variant (SNV) and copy number variant (CNV) profiles with treatment response (NCT05327010) |
| 15.353 Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19 |
| 15.354 CTIS2024-516402-32-00 Eligibility Criteria |
| 15.355 CTIS2024-516402-32-00 Primary Outcome 1 |
| 15.356 CTIS2024-516402-32-00 Secondary Outcome 1 |
| 15.357 CTIS2024-516402-32-00 Secondary Outcome 2 |
| 15.358 CTIS2024-516402-32-00 Secondary Outcome 3 |
| 15.359 CTIS2024-516402-32-00 Secondary Outcome 4 |
| 15.360 CTIS2024-516402-32-00 Secondary Outcome 5 |
| 15.361 CTIS2024-516402-32-00 Secondary Outcome 6 |
| 15.362 CTIS2024-516402-32-00 Secondary Outcome 7 |
| 15.363 CTIS2024-516402-32-00 Secondary Outcome 8 |
| 15.364 CTIS2025-523977-40-00 Eligibility Criteria - ARMYDA Study on Coronary Plaque Change with Semaglutide in Diabetes with ACS |
| 15.365 DatabaseCitation: Citation for FEvIR Platform |
| 15.366 DatabaseEntryCitation: ComparativeEvidenceReport: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
| 15.367 DatasetCitation: Extrachromosomal DNA Amplification Contributes to Small Cell Lung Cancer Heterogeneity and is Associated with Worse Outcomes |
| 15.368 DateOfFirstPublication Classification of FOI 153881 by Rachel Couban |
| 15.369 Death or Major Traumatic Injury 30 days after Impact comparing intervention vs. comparator |
| 15.370 Death or Major Traumatic Injury 30 days after Impact with comparator |
| 15.371 Death or Major Traumatic Injury 30 days after Impact with intervention |
| 15.372 Death or Major Traumatic Injury on Impact comparing intervention vs. comparator |
| 15.373 declined randomization in PARACHUTE Study |
| 15.374 deemed unsuitable by investigator in PARACHUTE Trial |
| 15.375 Delany-Moretlwe 2022 clinical trial |
| 15.376 Diabetes treatment medication |
| 15.377 Diastolic blood pressure at 12 weeks |
| 15.378 DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure |
| 15.379 DichotomousIntendedOutcome: Death or Major Traumatic Injury within 30 days |
| 15.380 DichotomousIntendedOutcome: New onset depression |
| 15.381 DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke |
| 15.382 DichotomousIntendedOutcome: Remission of diabetes |
| 15.383 DichotomousIntendedOutcome: Treatment with opioids |
| 15.384 DIO: Mortality |
| 15.385 Duration of response (NCT05327010) |
| 15.386 Eculizumab in hypertensive emergency-associated hemolytic uremic syndrome: a randomized multicenter controlled trial (HYPERSHU) |
| 15.387 Efficacy and Safety of a Quadruple Ultra-low-dose Treatment for Hypertension |
| 15.388 Efficacy of Corticosteroids in COVID-19 Patients: A Systematic Review and Meta-Analysis |
| 15.389 Eligibility criteria for NMA_Diabetes |
| 15.390 Eligibility Criteria for QUARTET USA Trial |
| 15.391 Enrolled Group for QUARTET USA Trial |
| 15.392 Enrolled Group PARACHUTE Trial |
| 15.393 Ethnic Group |
| 15.394 Ethnic Group with comparator |
| 15.395 Ethnic Group with intervention |
| 15.396 Evidence Based Medicine on FHIR Implementation Guide Code System |
| 15.397 Evidence for Results for Add-on Amlodipine at 6 weeks in GroupAssignment: Quadpill vs. Candesartan |
| 15.398 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Control Group |
| 15.399 Evidence for Results for Add-on Amlodipine at 6 weeks in QUARTET USA Trial Quadpill group |
| 15.400 Evidence for Results for Adverse event free and hypertension control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
| 15.401 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Control Group |
| 15.402 Evidence for Results for Adverse event free and hypertension control at 12 weeks in QUARTET USA Trial Quadpill group |
| 15.403 Evidence for Results for Diastolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
| 15.404 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Control Group |
| 15.405 Evidence for Results for Diastolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group |
| 15.406 Evidence for Results for Hypertension Control at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
| 15.407 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Control Group |
| 15.408 Evidence for Results for Hypertension Control at 12 weeks in QUARTET USA Trial Quadpill group |
| 15.409 Evidence for Results for Medication Adherence at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
| 15.410 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Control Group |
| 15.411 Evidence for Results for Medication Adherence at 12 weeks in QUARTET USA Trial Quadpill group |
| 15.412 Evidence for Results for Systolic blood pressure at 12 weeks in GroupAssignment: Quadpill vs. Candesartan |
| 15.413 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Control Group |
| 15.414 Evidence for Results for Systolic blood pressure at 12 weeks in QUARTET USA Trial Quadpill group |
| 15.415 Evidence List: Effect estimates for meta-analysis (Biegel 2020, Wang 2020, SOLIDARITY) |
| 15.416 EvidenceList: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis |
| 15.417 EvidenceReportSectionCode Value Set |
| 15.418 EvidenceReportSubject: Clinical Outcomes for Effects of Bariatric Surgery |
| 15.419 EvidenceVariable Handling Extension Value Set |
| 15.420 EvidenceVariable: case_id |
| 15.421 EvidenceVariable: Patient id |
| 15.422 EvidenceVariable: Time of measurement |
| 15.423 Example EndpointAnalysisPlan from PHUSE Lilly Redacted Protocol - EBMonFHIR IG Version |
| 15.424 Example of a ResearchStudySite |
| 15.425 Example of statistical model expression |
| 15.426 Excluded from PARACHUTE Study |
| 15.427 ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort |
| 15.428 ExposureVariable: Age (as continuous variable) |
| 15.429 ExposureVariable: Body Mass Index (as continuous variable) |
| 15.430 Family History of Parachute Use |
| 15.431 Family History of Parachute Use with comparator |
| 15.432 Family History of Parachute Use with intervention |
| 15.433 Frequent Flier |
| 15.434 Frequent Flier with comparator |
| 15.435 Frequent Flier with intervention |
| 15.436 Gene expression profiling (NCT05327010) |
| 15.437 GLP-1 RA Group in Adults with type 2 diabetes |
| 15.438 GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.439 GLP-1 RA Group in at-risk Adults with type 2 diabetes with moderate CV risk |
| 15.440 Glucagon Hydrochloride Solution (Active Comparator) |
| 15.441 Glucagon Nasal Powder (Experimental) |
| 15.442 Group Randomized to Comparator (empty backpack) in PARACHUTE Trial |
| 15.443 Group Randomized to Intervention Group (parachute) in PARACHUTE Trial |
| 15.444 GroupAssignment: Bariatric Surgery vs. no bariatric surgery |
| 15.445 GroupAssignment: ExposureDefinition: Bariatric Surgery (RYGB, VSG, LAGB, BPD) vs. ComparatorDefinition: NOT Bariatric Surgery (RYGB, VSG, LAGB, BPD) |
| 15.446 GroupAssignment: ExposureGroup: JAMA 2018 Norwegian cohort study Surgery cohort vs. ComparatorGroup: JAMA 2018 Norwegian cohort study Control cohort |
| 15.447 GroupAssignment: GLP-1 RA vs. Standard care |
| 15.448 GroupAssignment: high dose xanomeline vs. low dose xanomeline vs. placebo |
| 15.449 GroupAssignment: Jumping from aircraft with parachute vs. Jumping from aircraft with empty backpack |
| 15.450 GroupAssignment: Non Participants vs. Enrolled Participants |
| 15.451 GroupAssignment: Quadpill vs. Candesartan |
| 15.452 GroupAssignment: Roux-en-Y gastric bypass or Biliopancreatic Diversion vs. medical treatment |
| 15.453 GroupAssignment: Roux-en-Y gastric bypass surgery vs. Lifestyle-intensive medical management intervention alone |
| 15.454 GroupAssignment: Roux-en-Y gastric bypass vs. medical treatment |
| 15.455 GroupAssignment: SGLT2 inhibitors vs. GLP-1 RA |
| 15.456 GroupAssignment: Therapeutic-dose anticoagulation with heparin vs. Usual-care pharmacologic thromboprophylaxis |
| 15.457 Guideline: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes |
| 15.458 Health Survey Score Total |
| 15.459 Health Survey Score Total comparing intervention vs. comparator |
| 15.460 Health Survey Score Total with comparator |
| 15.461 Health Survey Score Total with intervention |
| 15.462 Health Survey Score-Mental Health Subscore |
| 15.463 Health Survey Score-Mental Health Subscore comparing intervention vs. comparator |
| 15.464 Health Survey Score-Mental Health Subscore with comparator |
| 15.465 Health Survey Score-Mental Health Subscore with intervention |
| 15.466 Health Survey Score-Physical Health Subscore |
| 15.467 Health Survey Score-Physical Health Subscore comparing intervention vs. comparator |
| 15.468 Health Survey Score-Physical Health Subscore with comparator |
| 15.469 Health Survey Score-Physical Health Subscore with intervention |
| 15.470 Health-related Quality of Life (NCT03640312) |
| 15.471 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at (NCT03640312) |
| 15.472 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312 |
| 15.473 Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312 |
| 15.474 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at (NCT03640312) |
| 15.475 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312 |
| 15.476 Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312 |
| 15.477 Height |
| 15.478 Height with comparator |
| 15.479 Height with intervention |
| 15.480 High Blood Pressure Medication Value Set |
| 15.481 History of Acrophobia |
| 15.482 History of Acrophobia with comparator |
| 15.483 History of Acrophobia with intervention |
| 15.484 History of Broken Bones |
| 15.485 History of Broken Bones with comparator |
| 15.486 History of Broken Bones with intervention |
| 15.487 History of Parachute Use |
| 15.488 History of Parachute Use with comparator |
| 15.489 History of Parachute Use with intervention |
| 15.490 Hypertension Control at 12 weeks |
| 15.491 ICD-10-GM Terminale Codes |
| 15.492 Incidence of adverse events (NCT05327010) |
| 15.493 Injury Severity Score 30 days after Impact comparing intervention vs. comparator |
| 15.494 Injury Severity Score 30 days after Impact with comparator |
| 15.495 Injury Severity Score 30 days after Impact with intervention |
| 15.496 Injury Severity Score on Impact comparing intervention vs. comparator |
| 15.497 Injury Severity Score on Impact with comparator |
| 15.498 Injury Severity Score on Impact with intervention |
| 15.499 International vs Domestic Flight |
| 15.500 International vs Domestic Flight with comparator |
| 15.501 International vs Domestic Flight with intervention |
| 15.502 InterventionDefinition: Glucagon-Like Peptide-1 (GLP-1) receptor agonists |
| 15.503 InterventionDefinition: Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors |
| 15.504 InterventionOnlyEvidence: Additional GI surgical procedure with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
| 15.505 InterventionOnlyEvidence: New onset depression with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
| 15.506 InterventionOnlyEvidence: Remission of diabetes with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
| 15.507 InterventionOnlyEvidence: Treatment with opioids with bariatric surgery (Intervention Group) in JAMA 2018 Norwegian cohort study |
| 15.508 Investigator |
| 15.509 Investigator-by-treatment interaction for ADAS-Cog(11) ANCOVA |
| 15.510 IV remdesivir 200 mg then 100 mg/day for 9 days |
| 15.511 Joanne Dehnbostel's Adaptation Report of Recommendation: ADA Obesity Management Recommendation 8.16 |
| 15.512 JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes |
| 15.513 JournalArticleCitation: Association of Bariatric Surgery with Complications and Comorbidities JAMA 2018 Norwegian Cohort |
| 15.514 Jumping from aircraft with empty backpack |
| 15.515 Jumping from aircraft with parachute |
| 15.516 Justification for Recommendation: ADA Obesity Management Recommendation 8.16 |
| 15.517 Justification for Recommendation: ADA Obesity Management Recommendation 8.17 |
| 15.518 M11 IGBJ Protocol Example Eligibility Criteria |
| 15.519 M11 Report for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.520 M11 Report for M11ResearchStudy Template |
| 15.521 M11 Report Section 1 (Protocol Summary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.522 M11 Report Section 1 (Protocol Summary) for M11ResearchStudy Template |
| 15.523 M11 Report Section 10 (Statistical Considerations) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.524 M11 Report Section 10 (Statistical Considerations) for M11ResearchStudy Template |
| 15.525 M11 Report Section 11 (Trial Oversight) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.526 M11 Report Section 11 (Trial Oversight) for M11ResearchStudy Template |
| 15.527 M11 Report Section 12 (Supporting Details) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.528 M11 Report Section 12 (Supporting Details) for M11ResearchStudy Template |
| 15.529 M11 Report Section 13 (Glossary) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.530 M11 Report Section 13 (Glossary) for M11ResearchStudy Template |
| 15.531 M11 Report Section 14 (References) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.532 M11 Report Section 14 (References) for M11ResearchStudy Template |
| 15.533 M11 Report Section 2 (Introduction) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.534 M11 Report Section 2 (Introduction) for M11ResearchStudy Template |
| 15.535 M11 Report Section 3 (Trial Objectives and Associated Estimands) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.536 M11 Report Section 3 (Trial Objectives and Associated Estimands) for M11ResearchStudy Template |
| 15.537 M11 Report Section 4 (Trial Design) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.538 M11 Report Section 4 (Trial Design) for M11ResearchStudy Template |
| 15.539 M11 Report Section 5 (Trial Population) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.540 M11 Report Section 5 (Trial Population) for M11ResearchStudy Template |
| 15.541 M11 Report Section 6 (Trial Intervention) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.542 M11 Report Section 6 (Trial Intervention) for M11ResearchStudy Template |
| 15.543 M11 Report Section 7 (Participant Discontinuation) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.544 M11 Report Section 7 (Participant Discontinuation) for M11ResearchStudy Template |
| 15.545 M11 Report Section 8 (Trial Assessments) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.546 M11 Report Section 8 (Trial Assessments) for M11ResearchStudy Template |
| 15.547 M11 Report Section 9 (Adverse Events) for A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus - M11 Example |
| 15.548 M11 Report Section 9 (Adverse Events) for M11ResearchStudy Template |
| 15.549 M11ResearchStudy Template |
| 15.550 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.551 MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.552 MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.553 MAGIC-derived ComparatorOnlyEvidence: Body weight in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.554 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.555 MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.556 MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.557 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.558 MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.559 MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.560 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.561 MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.562 MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.563 MAGIC-derived ComparatorOnlyEvidence: Heart failure in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.564 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.565 MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.566 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.567 MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.568 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.569 MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.570 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes |
| 15.571 MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.572 MAGIC-derived Evidence: All-cause mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.573 MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.574 MAGIC-derived Evidence: Body weight with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.575 MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.576 MAGIC-derived Evidence: Cardiovascular mortality with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.577 MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.578 MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.579 MAGIC-derived Evidence: End-stage kidney disease with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.580 MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.581 MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.582 MAGIC-derived Evidence: Health-related quality of life with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.583 MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.584 MAGIC-derived Evidence: Heart failure with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.585 MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.586 MAGIC-derived Evidence: Nonfatal myocardial infarction with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.587 MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.588 MAGIC-derived Evidence: Nonfatal stroke with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.589 MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.590 MAGIC-derived Evidence: Serious hyperglycaemia with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.591 MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.592 MAGIC-derived Evidence: Severe gastrointestinal events with GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.593 MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.594 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.595 MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.596 MAGIC-derived InterventionOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.597 MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.598 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.599 MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.600 MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.601 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.602 MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.603 MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.604 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.605 MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.606 MAGIC-derived InterventionOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.607 MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.608 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.609 MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.610 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.611 MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.612 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.613 MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.614 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes with moderate CV risk |
| 15.615 MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.616 MAGICapp-derived Group: GLP-1 RA Group in Adults with type 2 diabetes |
| 15.617 Major adverse cardiovascular events (composite endpoint) |
| 15.618 Mean Change in Blood Urea Nitrogen (NCT03640312) |
| 15.619 Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312 |
| 15.620 Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.621 Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.622 Mean Change in Serum Creatinine (NCT03640312) |
| 15.623 Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312 |
| 15.624 Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.625 Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.626 Mean Change in Serum Potassium (NCT03640312) |
| 15.627 Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312 |
| 15.628 Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.629 Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.630 Mean Change in Serum Sodium (NCT03640312) |
| 15.631 Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312 |
| 15.632 Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.633 Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.634 Mean Diastolic Blood Pressure (NCT03640312) |
| 15.635 Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 |
| 15.636 Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 |
| 15.637 Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.638 Mean Systolic Blood Pressure (NCT03640312) |
| 15.639 Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312 |
| 15.640 Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312 |
| 15.641 Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.642 Median Age of Parachute Intervention Group |
| 15.643 Medication Adherence (NCT03640312) |
| 15.644 Medication Adherence at 12 weeks |
| 15.645 Medication Adherence at 12 weeks for Candesartan in NCT03640312 |
| 15.646 Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.647 Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.648 Mental Health T Score at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.649 MetaanalysisEligibilityCriteria: Mean difference in HbA1c effect of bariatric surgery in type 2 diabetes and elevated BMI in 2016 meta-analysis |
| 15.650 MetaanalysisOutcomeDefinition: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up |
| 15.651 MetaanalysisStudyGroup: Effect Estimates for Mortality at 14 days from COVID19 Remdesivir vs. Placebo RCTs |
| 15.652 MetaanalysisStudyGroup: Study results included in Mean difference in HbA1c effect of bariatric surgery in 2016 meta-analysis |
| 15.653 Mortality at 14 days |
| 15.654 NCT03421379 Eligibility Criteria |
| 15.655 NCT03640312 Eligibility Criteria |
| 15.656 NCT04401202 Eligibility Criteria |
| 15.657 NCT04401202_Enrollment_Group |
| 15.658 NCT05327010 Eligibility Criteria |
| 15.659 NetEffectContribution for ComparativeEvidence: All-cause mortality effect of bariatric surgery in 2022 meta-analysis |
| 15.660 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Additional GI surgical procedure in JAMA 2018 Norwegian cohort study |
| 15.661 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Myocardial infarction or stroke in Swedish Obese Subjects (SOS) study |
| 15.662 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on New onset depression in JAMA 2018 Norwegian cohort study |
| 15.663 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Remission of diabetes in JAMA 2018 Norwegian cohort study |
| 15.664 NetEffectContribution for ComparativeEvidence: Bypass surgery effects on Treatment with opioids in JAMA 2018 Norwegian cohort study |
| 15.665 NetEffectContributionList: Bariatric Surgery Example for GIN 2022 |
| 15.666 NetEffectContributions: Bariatric Surgery Example for GIN 2022 |
| 15.667 NetEffectEstimate for SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022 |
| 15.668 NHANES LBDGLUSI Variable Definition Cohort Definition |
| 15.669 NHANES LBDGLUSI: Fasting Glucose (mmol/L) |
| 15.670 NHANES LBXGLU Variable Definition Cohort Definition |
| 15.671 NHANES LBXGLU: Fasting Glucose (mg/dL) |
| 15.672 NHANES Plasma Fasting Glucose (GLU_J) Data Dictionary |
| 15.673 NHANES SEQN Respondent Sequence Number |
| 15.674 NHANES WTSAF2YR Variable Definition Cohort Definition |
| 15.675 NHANES WTSAF2YR: Fasting Subsample 2 Year MEC Weight |
| 15.676 Norwegian Cohort Study Comparing Bariatric Surgery vs Medical Obesity Treatment for Long-term Medical Complications and Obesity-Related Comorbidities |
| 15.677 NT-proBNP Study Data Dictionary |
| 15.678 Number of Patients Requiring Step up Treatment (NCT03640312) |
| 15.679 Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312 |
| 15.680 Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312 |
| 15.681 Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.682 Objective response rate (ORR) (NCT05327010) |
| 15.683 Organ support-free days |
| 15.684 Outcome Importance Rating 100 of All-cause mortality |
| 15.685 Outcome Importance Rating 30 of Nonfatal myocardial infarction or stroke |
| 15.686 Outcome Importance Rating 5 of New onset depression |
| 15.687 Outcome Importance Rating 5 of Remission of diabetes |
| 15.688 Outcome Importance Rating 5 of Treatment with opioids |
| 15.689 Outcome Importance Rating 8 of Additional GI surgical procedure |
| 15.690 Outcome Importance Rating of DichotomousIntendedOutcome: Additional gastrointestinal surgical procedure for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study) |
| 15.691 Outcome Importance Rating of DichotomousIntendedOutcome: New onset depression for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study) |
| 15.692 Outcome Importance Rating of DichotomousIntendedOutcome: Nonfatal myocardial infarction or stroke for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study) |
| 15.693 Outcome Importance Rating of DichotomousIntendedOutcome: Remission of diabetes for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study) |
| 15.694 Outcome Importance Rating of DichotomousIntendedOutcome: Treatment with opioids for StudyEligibilityCriteria: Eligibility Criteria for Bariatric Surgery Randomized Trial (Diabetes Surgery Study) |
| 15.695 Outcome Importance Rating of Mortality for Bariatric Surgery Patients |
| 15.696 Outcome Measure List for QUARTET USA Trial |
| 15.697 Outcome Measure Report for QUARTET USA Trial |
| 15.698 Outcome Measure Report: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
| 15.699 Outcome Measures Report for NCT03421379 |
| 15.700 Outcome Measures Report for NCT03640312 |
| 15.701 Outcome Variables List for PARACHUTE Trial |
| 15.702 Outcome: Death or Major Traumatic Injury 30 days after Impact |
| 15.703 Outcome: Death or Major Traumatic Injury on Impact |
| 15.704 Outcome: Injury Severity Score 30 days after Impact |
| 15.705 Outcome: Injury Severity Score on Impact |
| 15.706 OutcomeDefinition for All-cause mortality |
| 15.707 OutcomeDefinition for Body weight |
| 15.708 OutcomeDefinition for Cardiovascular mortality |
| 15.709 OutcomeDefinition for End-stage kidney disease |
| 15.710 OutcomeDefinition for Health-related quality of life |
| 15.711 OutcomeDefinition for Heart failure |
| 15.712 OutcomeDefinition for Nonfatal myocardial infarction |
| 15.713 OutcomeDefinition for Nonfatal stroke |
| 15.714 OutcomeDefinition for Serious hyperglycaemia |
| 15.715 OutcomeDefinition for Severe gastrointestinal events |
| 15.716 OutcomeDefinition: Injury Severity Score on Impact |
| 15.717 OutcomeDefinition: All-cause mortality |
| 15.718 OutcomeDefinition: American Diabetes Association composite triple end point for metabolic control |
| 15.719 OutcomeDefinition: Body weight |
| 15.720 OutcomeDefinition: Cardiovascular mortality |
| 15.721 OutcomeDefinition: Diabetes in remission |
| 15.722 OutcomeDefinition: Diabetic ketoacidosis |
| 15.723 OutcomeDefinition: End-stage kidney disease |
| 15.724 OutcomeDefinition: Genital infection |
| 15.725 OutcomeDefinition: HbA1c at 12 months |
| 15.726 OutcomeDefinition: HbA1c at 24 months |
| 15.727 OutcomeDefinition: HbA1c at 36 months |
| 15.728 OutcomeDefinition: HbA1c at 6 months |
| 15.729 OutcomeDefinition: HbA1c at 60 months |
| 15.730 OutcomeDefinition: Health-related quality of life |
| 15.731 OutcomeDefinition: Heart failure |
| 15.732 OutcomeDefinition: Mortality at 14 days |
| 15.733 OutcomeDefinition: New onset depression |
| 15.734 OutcomeDefinition: Nonfatal myocardial infarction |
| 15.735 OutcomeDefinition: Nonfatal myocardial infarction or stroke |
| 15.736 OutcomeDefinition: Nonfatal stroke |
| 15.737 OutcomeDefinition: Serious hyperglycaemia |
| 15.738 OutcomeDefinition: Severe gastrointestinal events |
| 15.739 OutcomeList: Clinical Outcomes for Effects of Bariatric Surgery |
| 15.740 OutcomeMeasureReport: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.741 OutcomeVariable: American Diabetes Association composite triple end point for metabolic control at 5 years |
| 15.742 OutcomeVariable: HbA1c at 12 months |
| 15.743 OutcomeVariable: HbA1c at 24 months |
| 15.744 OutcomeVariable: HbA1c at 36 months |
| 15.745 OutcomeVariable: HbA1c at 6 months |
| 15.746 OutcomeVariable: HbA1c at 60 months |
| 15.747 OutcomeVariable: Mean difference in HbA1c between Surgery and Medical/Lifestyle groups at end of follow-up |
| 15.748 OutcomeVariable: New onset depression |
| 15.749 OutcomeVariable: Nonfatal myocardial infarction or stroke |
| 15.750 OutcomeVariable: Remission of diabetes |
| 15.751 OutcomeVariablesList: Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Complications and Obesity-Related Comorbidities (2018 Norwegian Cohort) |
| 15.752 OutcomeVariable_Additional_GI_surgical_procedure |
| 15.753 OutcomeVariable_All_cause_mortality |
| 15.754 OutcomeVariable_Treatment_with_opioids |
| 15.755 Overall survival (NCT05327010) |
| 15.756 PARACHUTE Trial baseline characteristics |
| 15.757 PARACHUTE Trial non participants |
| 15.758 PARACHUTE trial participant flow report |
| 15.759 PARACHUTE Trial Participants |
| 15.760 PARACHUTE Trial Participants assigned an empty backpack |
| 15.761 PARACHUTE trial participants assigned parachute |
| 15.762 PARACHUTE Trial Participants available for randomization |
| 15.763 PARACHUTE Trial Participants deemed unsuitable by investigator |
| 15.764 PARACHUTE Trial Participants randomized into groups |
| 15.765 PARACHUTE Trial Participants randomized into groups for screened group |
| 15.766 PARACHUTE Trial Participants randomized into groups with comparator |
| 15.767 PARACHUTE Trial Participants randomized into groups with intervention |
| 15.768 PARACHUTE Trial Participants that completed 30 day follow up |
| 15.769 PARACHUTE Trial Participants that completed 30 day follow up with comparator |
| 15.770 PARACHUTE Trial Participants that completed 30 day follow up with intervention |
| 15.771 PARACHUTE Trial Participants that completed jump and 5 minute follow-up |
| 15.772 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with comparator |
| 15.773 PARACHUTE Trial Participants that completed jump and 5 minute follow-up with intervention |
| 15.774 PARACHUTE Trial Participants that declined randomization |
| 15.775 PARACHUTE Trial Participants with no contact at 30 days |
| 15.776 PARACHUTE Trial Participants with no contact at 30 days with comparator |
| 15.777 PARACHUTE Trial Participants with no contact at 30 days with intervention |
| 15.778 PARACHUTE Trial Results |
| 15.779 Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. |
| 15.780 Parachute vs Empty Backpack in PARACHUTE Trial |
| 15.781 Participant Flow Report for NCT03421379 |
| 15.782 Participant Flow Report for NCT03640312 |
| 15.783 Participant Flow Report for QUARTET USA Trial |
| 15.784 Participant Flow Variables List for PARACHUTE Trial |
| 15.785 ParticipantFlow: 2018 Norwegian Cohort Included in Analysis |
| 15.786 ParticipantFlow: 2018 Norwegian Cohort Medical Group Included in Analysis |
| 15.787 ParticipantFlow: 2018 Norwegian Cohort Surgical Group Included in Analysis |
| 15.788 ParticipantFlowEvidence: 2018 Norwegian Cohort Excluded from Analysis |
| 15.789 ParticipantFlowMeasure: Dropout due to stopping intervention |
| 15.790 ParticipantFlowMeasure: Exclusion from analysis |
| 15.791 ParticipantFlowMeasure: Inclusion in analysis |
| 15.792 Participants Excluded from PARACHUTE Study |
| 15.793 Participants_in_Anticoagulation_for_COVID_19_Combined_ATTACC_ACTIV_4a_and_REMAP_CAP_RCT_hospitalized_not_critically_ill |
| 15.794 Patients_who_are_hospitalized_for_COVID_19_and_who_are_not_critically_ill |
| 15.795 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) |
| 15.796 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 |
| 15.797 PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 |
| 15.798 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia (NCT03421379) |
| 15.799 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 |
| 15.800 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration for Glucagon Nasal Powder in NCT03421379 |
| 15.801 Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia at Pre-dose up to 30 minutes post each glucagon administration Statistical Analysis for Glucagon Nasal Powder vs Glucagon Hydrochloride Solution in NCT03421379 |
| 15.802 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization (NCT04401202) |
| 15.803 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Control in Nigella Sativa for COVID-19 OSF Preprint |
| 15.804 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization - for Nigella Sativa Oil in Nigella Sativa for COVID-19 OSF Preprint |
| 15.805 Percentage of Participants With Clinical Recovery Within 14 Days After Randomization Statistical Analysis for Nigella Sativa Oil vs Control in Nigella Sativa for COVID-19 OSF Preprint |
| 15.806 Percentage of Participants With Potentially Related Adverse Events (NCT03640312) |
| 15.807 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312 |
| 15.808 Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.809 Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.810 Percentage of Participants With Serious Adverse Events (SAEs) (NCT03640312) |
| 15.811 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312 |
| 15.812 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.813 Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.814 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) (NCT03421379) |
| 15.815 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 |
| 15.816 Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM) at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 |
| 15.817 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) |
| 15.818 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 |
| 15.819 Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 |
| 15.820 Physical Health T Score at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.821 PICO: Intensive versus standard blood-pressure control for major adverse cardiovascular events in adults at increased cardiovascular risk |
| 15.822 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) |
| 15.823 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 |
| 15.824 PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 |
| 15.825 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM (NCT03421379) |
| 15.826 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Hydrochloride Solution in NCT03421379 |
| 15.827 PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM at Pre-dose, 5, 10, 15, 20, 25, 30, 40, 50, 60, 90, 120, 240 minutes after each glucagon administration for Glucagon Nasal Powder in NCT03421379 |
| 15.828 Placebo |
| 15.829 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.16 |
| 15.830 PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17 |
| 15.831 PreprintCitation: Nigella Sativa for COVID-19 OSF Preprint |
| 15.832 Progression-free survival (NCT05327010) |
| 15.833 Proportion of Patients With Adverse Event Free Hypertension Control (NCT03640312) |
| 15.834 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312 |
| 15.835 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.836 Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.837 Proportion of Patients With Hypertension Control (NCT03640312) |
| 15.838 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at (NCT03640312) |
| 15.839 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312 |
| 15.840 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.841 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at (NCT03640312) |
| 15.842 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312 |
| 15.843 Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312 |
| 15.844 Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.845 Quadpill once daily |
| 15.846 QUARTET USA Trial Control Group |
| 15.847 QUARTET USA Trial Quadpill group |
| 15.848 randomized into groups for PARACHUTE Trial |
| 15.849 Rate of Adverse Events of Special Interest (NCT03640312) |
| 15.850 Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312 |
| 15.851 Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312 |
| 15.852 Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 |
| 15.853 Rate of Death or Major Traumatic Injury on Impact with comparator |
| 15.854 Rate of Death or Major Traumatic Injury on Impact with intervention |
| 15.855 Reasons for exclusion from QUARTET USA Trial |
| 15.856 Recommendation Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17) |
| 15.857 Recommendation Justification Code System |
| 15.858 Recommendation Rating: ADA Obesity Management Recommendation 8.16 |
| 15.859 Recommendation: ADA Obesity Management Recommendation 8.16 |
| 15.860 Recommendation: ADA Obesity Management Recommendation 8.16-adapted |
| 15.861 Recommendation: ADA Obesity Management Recommendation 8.17 |
| 15.862 RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.16) |
| 15.863 Remdesivir |
| 15.864 Remdesivir IV 200 mg once then 100 mg once daily for 9 days |
| 15.865 ResearchStudy Classifier Code System |
| 15.866 Results Section for NCT03421379 |
| 15.867 Results Section for NCT03640312 |
| 15.868 Risk of Bias Assessment of Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19 |
| 15.869 Risk of Bias Assessment of PARACHUTE trial |
| 15.870 Risk Of Bias Type Value Set |
| 15.871 Screened Group PARACHUTE Trial |
| 15.872 Search Strategy for NMA_Diabetes |
| 15.873 SearchResults: PubMed search for Wonder Woman |
| 15.874 SearchStrategy: PubMed and Embase search for van Veldhuisen 2022 systematic review |
| 15.875 SearchStrategy: PubMed search for Wonder Woman |
| 15.876 Sex |
| 15.877 Sex with comparator |
| 15.878 Sex with intervention |
| 15.879 SGLT2 inhibitors Group in Adults with diabetes mellitus type 2 |
| 15.880 SGLT2 inhibitors Group in Adults with type 2 diabetes |
| 15.881 SMR-excluded Tlayjeh H J Infect Public Health 33008778 |
| 15.882 SoaPlanDefinition: Follow-up assessment 3 months after study start |
| 15.883 SoftwareCitation: Computable Publishing®: ClinicalTrials.gov-to-FEvIR Converter |
| 15.884 Spanish or English Value Set |
| 15.885 Standard care Group in Adults with type 2 diabetes with moderate CV risk |
| 15.886 StudyCitation: 2022 Systematic Review of bariatric surgery mortality effect 35243488 |
| 15.887 StudyEligibilityCriteria for M11Report Example |
| 15.888 StudyEligibilityCriteria: Eligibility Criteria for DIBASY Trial |
| 15.889 StudyEligibilityCriteria: Obese patients ≥ 18 years old |
| 15.890 StudyEligibilityCriteria: Type 2 diabetes and elevated BMI in 2016 meta-analysis |
| 15.891 StudyEligibilityCriteria_Eligibility_Criteria_for_Bariatric_Surgery_Randomized_Trial_Diabetes_Surgery_Study |
| 15.892 StudyGroup: Diabetes Surgery Study Trial Enrollment Group |
| 15.893 StudyGroup: Severely Obese Adults 2018 Norwegian Cohort |
| 15.894 StudyGroup_DIBASY_Trial_Enrollment_Group |
| 15.895 Summary of Findings - QUARTET USA Trial |
| 15.896 SummaryOfFindings: Bariatric Surgery Summary of Findings Example for GIN 2022 |
| 15.897 SummaryOfFindings: GLP-1 RA vs. Standard care in Adults with type 2 diabetes with moderate CV risk |
| 15.898 SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes |
| 15.899 SummaryOfNetEffect: Bariatric Surgery Summary of Net Effect Contributions Example for GIN 2022 |
| 15.900 SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
| 15.901 SystematicReviewExcludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
| 15.902 SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer |
| 15.903 Systolic blood pressure at 12 weeks |
| 15.904 Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial |
| 15.905 Time to integration of results in a recommendation |
| 15.906 Treatment-induced changes in phospho-protein signaling (NCT05327010) |
| 15.907 VariableDefinition: Comparator |
| 15.908 VariableDefinition: Condition(s) |
| 15.909 VariableDefinition: Date of birth |
| 15.910 VariableDefinition: Date of measurement |
| 15.911 VariableDefinition: Gender |
| 15.912 VariableDefinition: NTproBNP |
| 15.913 VariableDefinition: Unit |
| 15.914 Velocity |
| 15.915 Velocity comparing intervention vs. comparator |
| 15.916 Velocity for enrolled group |
| 15.917 Velocity for non participant group |
| 15.918 Velocity with comparator |
| 15.919 Velocity with intervention |
| 15.920 WebPageCitation: A HEvKA Update Summary |
| 15.921 Weight |
| 15.922 Weight with comparator |
 15.923 Weight with intervention |
|
Propose a change